Articles

Find an Article

Filter articles

Applied Filters

Showing 41 to 50 of 274 results

LSIPR 50 2018: Alisa Harbin

Switzerland17-08-2018

Alisa Harbin was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.

Combination SPCs: shaken and stirred

UK14-08-2018Joel Beevers and Michael Pears

Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate.

LSIPR 50 2018: Emma Walmsley

UK09-08-2018

Emma Walmsley was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2018: Antoine Petit

France08-08-2018

Antoine Petit was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2018: Kim Nasmyth

UK03-08-2018

Kim Nasmyth was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2018: Manuel Salmeron-Sanchez and Matthew Dalby

UK01-08-2018

Manuel Salmeron-Sanchez and Matthew Dalby were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2018: Michel Sidibé

Switzerland31-07-2018

Michel Sidibé was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

The future of precision medicine part 2: data is king

International, UK17-07-2018Daniel Lim

In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

EPO13-07-2018Jakob Wested, Timo Minssen, Esther van Zimmeren

As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.

LSIPR 50 2018: At the head of an experiment in innovation

France09-07-2018

Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.

Showing 41 to 50 of 274 results

LSIPR